SML3200
MK-0608
≥98% (HPLC)
别名:
2′-C-Methyl-7-deaza-adenosine, 4-Amino-7-(2-C-methyl-[beta]-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine, 7′DMA, 7-(2-C -Methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d ]pyrimidin-4-amine, 7-DMA, 7-Deaza-2’-C-methyladenosine, 7-Deaza-2’-CMA, 7DMA, MK 0608, MK 608, MK-608, MK0608, MK608
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H16N4O4
化学文摘社编号:
分子量:
280.28
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
SMILES string
[n]2(c3ncnc(c3cc2)N)[C@@H]1O[C@@H]([C@H]([C@]1(O)C)O)CO
InChI
1S/C12H16N4O4/c1-12(19)8(18)7(4-17)20-11(12)16-3-2-6-9(13)14-5-15-10(6)16/h2-3,5,7-8,11,17-19H,4H2,1H3,(H2,13,14,15)/t7-,8-,11-,12-/m1/s1
InChI key
IRZRJANZDIOOIF-GAJNKVMBSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -155 to -185°, c = 1 in methanol
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
MK-0608 (7DMA; 2′-C-Methyl-7-deaza-adenosine; 7-Deaza-2′-C-methyladenosine) is an orally active antiviral nucleoside analog that inhibits hepatitis C virus (HCV genotype 1b replicon IC50/90 = 0.3/1.3 ?M) and Zika virus (ZIKV strain MR766 IC50 = 1.3-9.6 μM) replication by targeting viral RNA-dependent RNA polymerase. MK-0608 effectively reduces viral load in HCV-infected (0.2-2 mg/kg chimpanzees via daily i.v. or p.o.; 3-50 mg/kg mice b.i.s. p.o.) and ZIKV-infected animals in vivo (50 mg/kg mice via daily p.o.).
Orally active antiviral nucleoside analog that inhibits hepatitis C virus (HCV) and Zika virus (ZIKV) replication in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持